BerGenBio is considered an inspirational example by Norway’s PM Erna Solberg during her New Year address to the nation

Bergen, Norway, January 2, 2017 – Leading oncology biopharmaceutical company BerGenBio AS, today announced that it felt proud to have been identified as inspirational example of successful Norwegian entrepreneurialism as portrayed by Norway’s prime minister Erna Solberg during her January 1 New Year address to the nation.
Richard Godfrey, CEO of BerGenBio, commented:
“We are honoured, proud and grateful that Prime minister Erna Solberg chose our ongoing business success story to illustrate the importance of ‘individual initiative and entrepreneurialism’ to secure the Norwegian future economic growth.
“Thanks to the vision, dedication and creativity of our scientists and the continuing support by our investors we have built a world class biotech company in Bergen. Our mission is to develop first-in-class drugs for aggressive cancers and we are very excited to have recently reported encouraging clinical data from patients with both leukeamia and lung cancer. So far we have provided our lead drug candidate, BGB324, to more than 80 patients around the world and we will expand our clinical trials further in 2017.
Recognition and acknowldgement by the Prime Minister is very motivational as we pioneer new treatments for our patients worldwide.”
-Ends-
For further information please contact:
BerGenBio AS
+47 917 86 304
Richard Godfrey, CEO
Media enquiries
RHA
+44 (0) 7711 821 527
Richard Hayhurst
About BerGenBio AS
BerGenBio AS is a clinical stage biopharmaceutical company focused on developing first-in-class drugs for aggressive cancers. The company is a world leader in understanding the biology of epithelial-mesenchymal transition (EMT), a widely recognised key pathway of immune evasion, acquired cancer drug-resistance and metastasis. BerGenBio AS is founded on proprietary platform technology, CellSelect™, to identify and validate novel drug targets and biomarkers. The company has progressed its lead drug candidate BGB324, an Axl inhibitor, into clinical trials in AML and NSCLC, while pursuing the pre-clinical development of additional compounds and proprietary EMT drug targets. For further information, please visit www.bergenbio.com and you can also follow us on Twitter at @BGenBio or LinkedIn at linkedin.com/company/bergenbio-as